Share price
$10.03
As of Apr 29, 2026
IMUX | NASDAQ
Immunic, Inc.
Immunic, Inc. (IMUX) | runway -1.8 months | financing risk high | market cap $146.4M. Daily snapshot of financials, capital pressure, and recent developments.
Company websiteLast updated Apr 29, 2026
Market cap
$146.4M
Snapshot valuation
30D volume
274,418 shares
Rolling average daily volume
Runway
-1.8 months
Estimated from precomputed burn and cash
Financing risk
N/A
The company screens as likely to return to the capital markets soon.
Snapshot summary
Runway: -1.8 months based on estimated burn.
Recent financing detected on Feb 26, 2026.
Financing signal: The company screens as likely to return to the capital markets soon.
Recent developments
IMMUNIC, INC. 8-K 2026-04-14
8-K filed on 2026-04-14.
IMMUNIC, INC. 8-K 2026-04-10
8-K filed on 2026-04-10.
Immunic to Participate in Scientific and Medical Conferences in April
NEW YORK, April 9, 2026 – Immunic, Inc.(Nasdaq: IMUX),a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April: About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. […]
IMMUNIC, INC. S-3 2026-04-02
S-3 filing submitted on 2026-04-02.
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK, April 1, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 27, 2026, informing the company that it has […]
Related screens
Low cash runway companies
Companies screening with the shortest estimated runway based on precomputed burn and cash snapshots.
High burn rate companies
Companies with the highest estimated trailing cash burn across the monitored issuer set.
Recent financing disclosures
Companies with recent financing activity, capital raises, or post-balance-sheet funding events.
Pre-market filings
Companies with recent filings or disclosures posted before the market open.
Related companies
Recent documents
IMMUNIC, INC. 8-K 2026-04-14
8-K filed on 2026-04-14.
Apr 13, 2026Open source
IMMUNIC, INC. 8-K 2026-04-10
8-K filed on 2026-04-10.
Apr 9, 2026Open source
Immunic to Participate in Scientific and Medical Conferences in April
NEW YORK, April 9, 2026 – Immunic, Inc.(Nasdaq: IMUX),a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April: About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. […]
Apr 9, 2026Open source
IMMUNIC, INC. S-3 2026-04-02
S-3 filing submitted on 2026-04-02.
Apr 1, 2026Open source
Premium analysis
Full filing analysis and proprietary signal detail
Detailed impact scoring, historical financial trends, full filing analysis, premium alerts, and proprietary signal explanations stay behind login and subscription.
Full filing analysis with event-level impact scoring
Historical financial trends and runway context
Detailed signal breakdowns and proprietary explanations
Premium alerts, filters, and watchlist workflows
Deeper financing and dilution analysis
Timeline context across filings and disclosures